YOUR SEARCH FOR Text 163 RESULTS
1 of Total
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Derm
… View all news Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American … Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American …
2 of Total
Understanding Hidradenitis Suppurativa (HS) | Incyte Stories
… August 28, 2024 Understanding Hidradenitis … Understanding Hidradenitis Suppurativa (HS) | Incyte …
3 of Total
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Derm
… Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at …
4 of Total
Incyte Leadership | Incyte.com
… Our Leadership Executive Team Bill Meury Chief … Company’s Board of Directors. With over three decades of industry experience, Mr. Meury is a …
5 of Total
Incyte Announces Executive Leadership Appointments | Incyte
… View all news Incyte Announces Executive Leadership … Incyte Announces Executive Leadership Appointments | Incyte …
6 of Total
Headquarters - Pharmaceutical Research & Development | Incyte.com
… Our Locations HEADQUARTERS OTHER LOCATIONS NORTH … AMERICA 1801 Augustine Cut-off Wilmington, DE 19803 +1 1.855.4.INCYTE (+1 1.855.446.2983) …
7 of Total
A Day in the Life–Kelly Federowicz | Incyte Stories
… August 1, 2025 A Day in the Life—Kelly … A Day in the Life–Kelly Federowicz | Incyte …
8 of Total
A Day in the Life–Carine Delattre | Incyte Stories
… February 21, 2025 A Day in the Life—Carine Delattre … A Day in the Life–Carine Delattre | Incyte Stories …
9 of Total
Understanding Diffuse Large B-cell Lymphoma (DLBCL) | Incyte Stories
… September 14, 2023 Understanding Diffuse Large B-cell Lymphoma (DLBCL) A … Understanding Diffuse Large B-cell Lymphoma …
10 of Total
Portfolio: MPNs & GVHD, Hematology/Oncology, Dermatology & Inflammation and Autoimmunity
… Explore Our Science We have a breadth of clinical trial programs across … and Autoimmunity (IAI). NAVIGATE TO PORTFOLIO DETAILS CLINICAL TRIALS Our Portfolio Molecular …